# CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance
Canonical URL: https://biopharmsignal.com/news/CVRX/cvrx-reports-preliminary-fourth-quarter-and-fiscal-year-2025-financial-results-and-issues-fiscal-2026-guidance
Ticker: CVRX
Company: CVRx
Source: CVRx
Published: 2026-01-12 13:00 EST
Original Source URL: https://ir.cvrx.com
## Summary

Fourth quarter revenue expected to be $15.9 million to $16.1 million, representing growth of 4% to 5% Full year revenue expected to be $56.5 million to $56.7 million, representing growth of 10% to 11% Fiscal 2026 revenue expected to be between $63 million and $67 million, representing growth of 11%

## Article Body
Fourth quarter revenue expected to be $15.9 million to $16.1 million, representing growth of 4% to 5% Full year revenue expected to be $56.5 million to $56.7 million, representing growth of 10% to 11% Fiscal 2026 revenue expected to be between $63 million and $67 million, representing growth of 11%
## Recent Company News
- 2026-05-27 20:30 EST — [CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/CVRX/cvrx-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference) — Source: CVRx
- 2026-05-20 20:30 EST — [CVRx to Present at the William Blair 46th Annual Growth Stock Conference](https://biopharmsignal.com/news/CVRX/cvrx-to-present-at-the-william-blair-46th-annual-growth-stock-conference) — Source: CVRx
- 2026-05-14 12:00 EST — [CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy](https://biopharmsignal.com/news/CVRX/cvrx-announces-humana-medicare-advantage-coverage-policy-for-barostim-therapy) — Source: CVRx
- 2026-05-11 20:05 EST — [CVRx Reports First Quarter 2026 Financial and Operating Results](https://biopharmsignal.com/news/CVRX/cvrx-reports-first-quarter-2026-financial-and-operating-results) — Source: CVRx
- 2026-05-04 20:30 EST — [CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population](https://biopharmsignal.com/news/CVRX/cvrx-announces-first-patient-enrollment-in-benefit-hf-a-landmark-heart-failure-trial-evaluating-barostim-in-significantly-expanded-population) — Source: CVRx
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)